Applied Clinical Trials-06-01-2020

Recent surveys of the public and patients concerning COVID-19 highlight the larger issue around health and/or scientific literacy among the general public.

Clinical trial stakeholders weigh in on the major shifts unfolding in the era of COVID-19, as efforts move away from the traditional site-based model.

Aligning approaches in quality, control, and oversight to get the most out of including home visits in clinical trial protocols.

How integrated data platforms can help find the best-suited patients for cancer studies and reduce the burden on care teams.

Outlining the five critical hurdles faced by clinical teams conducting studies in these nations amid quarantine and other restrictions.

The only way for pharma companies to know where to focus their COVID-19 R&D efforts is for the industry to have access to real-time, real-world evidence of what’s working to keep people alive, write Travis Leonardi and William Kirsh.

AI presents rare opportunity to assess the scope of this longtime challenge.

This proliferation of vaccine research programs emphasizes the importance of carrying out clinical trials that utilize similar protocols and endpoints able to produce comparable results.

CEO of clinical development analytical company shares findings from a recent data analysis of 300,000 global clinical trial sites to assess the impact of COVID-19.

With the push for the earliest possible release of clinical study reports for COVID-19 treatments, European regulators and reimbursement agencies might experience a heightened vulnerability, as public expectation about coronavirus cures rises.

A compilation of recent notable news developments that pertain to the clinical trials industry.

Click the title above to open the Applied Clinical Trials June 2020 issue in an interactive PDF format.